This dispatch covers Semax and Cognitive Enhancement: Mechanisms and Applications in the Cognitive research category, authored by Petrov, A., Singh, R., originally published in Neuropharmacology Today on December 5, 2023. It has been cited 67 times and takes approximately 14 minutes to read. The Peptide Dispatch curates peer-reviewed peptide research for self-directed learners. All summaries are presented for Research Use Only and do not constitute medical advice.
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic ACTH 4-10 analog developed in 1980s Russia and is one of the few peptide nootropics with formal regulatory approval anywhere in the world (Russia, for ischaemic-stroke recovery). Mechanistically, the most-replicated pathway is BDNF upregulation in the hippocampus, prefrontal cortex, and basal forebrain following intranasal administration, with downstream effects on long-term potentiation and spatial learning in rodents. A neuroprotective effect is reported in MCAO rodent stroke models (25-40% infarct volume reduction). The Russian human clinical literature on stroke is the largest dataset and is directionally consistent — improved NIHSS and modified-Rankin scores at 30 days when administered within 6-12 hours of symptom onset — but methodological quality varies (blinding, sample size, standardised endpoints). Outside Russia, large independent RCTs are absent and the peptide is unscheduled by the FDA. Safety signals at typical doses (250-1000 ug intranasal) are reassuring; long-term safety in healthy users is uncharacterised.
Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed in the 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences as a synthetic analog of a fragment of adrenocorticotropic hormone (ACTH 4-10) with the intent of preserving the neuromodulatory properties of the parent hormone while eliminating its corticosteroid-releasing activity. Over the subsequent four decades, Semax has been extensively investigated in Russian and Eastern European preclinical and clinical literature, and is among a small handful of peptide nootropics with formal regulatory approval in any jurisdiction (Semax is registered in Russia for clinical use in ischaemic-stroke recovery and for cognitive impairment associated with cerebrovascular disease). This dispatch synthesises mechanistic and clinical findings across the published literature, with attention to the gap between the substantial Russian-language clinical data and the comparatively sparse Western preclinical replication. The most-characterised mechanism involves brain-derived neurotrophic factor (BDNF). Multiple rodent studies have shown that intranasal Semax administration (the standard route in clinical use) increases BDNF expression in the hippocampus, prefrontal cortex, and basal forebrain within hours of dosing, with effects detectable by both qPCR and Western blot for at least 24 hours post-administration. The downstream consequences in animal models include enhanced long-term potentiation in hippocampal slice preparations, improved performance in Morris water-maze and Y-maze spatial learning tasks, and protection against scopolamine-induced cognitive impairment. A second mechanistic axis involves the endogenous opioid system: Semax appears to modulate enkephalin degradation and may indirectly enhance opioid-receptor-mediated signalling in pain and stress pathways, though this mechanism is less consistently characterised than the BDNF pathway. A third proposed mechanism — direct neuroprotection a…
All information is presented for Research Use Only (RUO). Not medical advice.